10-Q/A

                      SECURITIES AND EXCHANGE COMMISSION  

                             Washington, D.C.  20549  
                      ___________________________________  

  
                                   FORM 10-Q/A
                                (Amendment No. 1)


               QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D)
                   OF THE SECURITIES EXCHANGE ACT OF 1934

  
                                      OR  

  
                  For the quarterly period ended June 30, 1996

  
                         Commission File No. 0-15360  

  
                       BIOJECT MEDICAL TECHNOLOGIES INC.  
          (Exact name of registrant as specified in its charter)  


  
           Oregon                                       93-1099680  
(State of other jurisdiction of                (I.R.S. identification no.)  
 employer incorporation or organization)  


  
       7620 SW Bridgeport Road  
           Portland, Oregon                                 97224  
(Address of principal executive offices)                 (Zip code)  


  
                               (503) 639-7221  
           (Registrant's telephone number, including areas code)  
  

     Indicate by check mark whether the registrant (1) has filed all reports  
required to be filed by Section 13 or 15(d) of the Securities Exchange Act
of 1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to   
such filing requirements for the past 90 days.  Yes [X]   No [ ]  

     At June 30, 1996 there were 15,616,712 outstanding shares of common stock
of the registrant.






                             INDEX TO EXHIBITS



Exhibit No.            Exhibit Description
- -----------            -------------------------------
   27                  Financial Data Schedule




                                SIGNATURE




Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the 
undersigned thereunto duly authorized.



                               BIOJECT MEDICAL TECHNOLOGIES INC.
                               (Registrant)  



Date:  October 2, 1996         /S/ Peggy J. Miller
                               ---------------------------------
                               Peggy J. Miller
                               Vice President and Chief Financial Officer

EX-27

 

<ARTICLE> 5
<MULTIPLIER> 1
       
                             
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          MAR-31-1996
<PERIOD-END>                               JUN-30-1996
<CASH>                                       2,753,489
<SECURITIES>                                         0
<RECEIVABLES>                                   72,710
<ALLOWANCES>                                         0
<INVENTORY>                                  1,517,180
<CURRENT-ASSETS>                             4,391,161
<PP&E>                                       2,728,804
<DEPRECIATION>                               1,213,338
<TOTAL-ASSETS>                               6,381,184
<CURRENT-LIABILITIES>                          968,437
<BONDS>                                        450,000
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                    36,160,508
<OTHER-SE>                                           0
<TOTAL-LIABILITY-AND-EQUITY>                 6,381,184
<SALES>                                        176,869
<TOTAL-REVENUES>                               491,769
<CGS>                                          581,542
<TOTAL-COSTS>                                  581,542
<OTHER-EXPENSES>                             1,134,123
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                   0
<INCOME-PRETAX>                            (1,223,896)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                        (1,223,896)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                               (1,223,896)
<EPS-PRIMARY>                                    (.08)
<EPS-DILUTED>                                    (.08)